➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Medtronic
AstraZeneca
Dow
Boehringer Ingelheim
Colorcon
Express Scripts

Last Updated: October 1, 2020

DrugPatentWatch Database Preview

Patent: 7,211,593

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,211,593
Title:C12-cyano epothilone derivatives
Abstract: The present invention relates to compounds useful in the treatment of cancer or other proliferative diseases represented by the formula ##STR00001## wherein: R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5 are hydrogen or lower alkyl; R.sub.6 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, aryl, substituted aryl, cycloalkyl, or heterocyclo; X is hydrogen and Y is hydroxy, or X and Y taken together represent a carbon-carbon bond; and pharmaceutically acceptable salts, solvates, or hydrates thereof. Also included are therapeutic compositions containing the compounds represented by formula I as active ingredients, alone or in combination with other therapeutic agents useful in the treatment of cancer or other proliferative diseases.
Inventor(s): Vite; Gregory D. (Titusville, NJ), Regueiro-Ren; Alicia (Middletown, CT)
Assignee: Bristol-Myers Squibb Co. (Princeton, NJ)
Application Number:10/386,059
Patent Claims:see list of patent claims

Details for Patent 7,211,593

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 002 2017-06-22   Start Trial Bristol-Myers Squibb Co. (Princeton, NJ) 2022-03-12 RX Orphan search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 001 2017-06-22   Start Trial Bristol-Myers Squibb Co. (Princeton, NJ) 2022-03-12 RX Orphan search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 002 1997-11-26   Start Trial Bristol-Myers Squibb Co. (Princeton, NJ) 2022-03-12 RX search
Genentech RITUXAN rituximab SOLUTION;INTRAVENOUS 103705 001 1997-11-26   Start Trial Bristol-Myers Squibb Co. (Princeton, NJ) 2022-03-12 RX search
Berlex Labs LEUKINE sargramostim VIAL 103362 002 1991-03-05   Start Trial Bristol-Myers Squibb Co. (Princeton, NJ) 2022-03-12 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Boehringer Ingelheim
Merck
Express Scripts
Moodys
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.